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ABSTRACT
Beclin 1 (BECN1) is a multifunctional protein that activates the pro-
autophagic class III phosphatidylinositol 3-kinase (PIK3C3, best known as 
VPS34), yet also interacts with multiple negative regulators. Here we report 
that BECN1 interacts with inhibitor of growth family member 4 (ING4), a 
tumor suppressor protein that is best known for its capacity to interact 
with the tumor suppressor protein p53 (TP53) and the acetyltransferase 
E1A binding protein p300 (EP300). Removal of TP53 or EP300 did not 
affect the BECN1/ING4 interaction, which however was lost upon culture 
of cells in autophagy-inducing, nutrient free conditions. Depletion of ING4 
stimulated the enzymatic activity of PIK3C3, as visualized by means of a red 
fluorescent protein-tagged short peptide (FYVE) that specifically binds to 
phosphatidylinositol-3-phosphate (PI3P)-containing subcellular vesicles and 
enhanced autophagy, as indicated by an enhanced lipidation of microtubule-
associated proteins 1A/1B light chain 3 beta (LC3B) and the redistribution 
of a green-fluorescent protein (GFP)-LC3B fusion protein to cytoplasmic 
puncta. The generation of GFP-LC3B puncta stimulated by ING4 depletion 
was reduced by simultaneous depletion, or pharmacological inhibition, of 
PIK3C3/VPS34. In conclusion, ING4 acts as a negative regulator of the lipid 
kinase activity of the BECN1 complex, and starvation-induced autophagy is 
accompanied by the dissociation of the ING4/BECN1 interaction.
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INTRODUCTION
Macroautophagy, to which we refer as ‘autophagy’, 
is a catabolic process that cells use to cope with stressful 
conditions such as nutrient deprivation, organelle 
dysfunction or invasion of the cytoplasm by infectious 
pathogens [1, 2]. Alterations in autophagy are linked to 
multiple diseases, including aging [3], cancer [4], and 
neurodegenerative disorders [5]. Autophagy consists 
in the sequestration of cytoplasmic material in double-
membraned vesicles (autophagosomes) that fuse with 
lysosome (autophagolysosomes) where the luminal 
content is degraded by the action of hydrolases operating 
at low pH [6].
The formation of autophagosomes is finely regulated 
by the concerted action of protein kinases, in particular 
unc-51 like autophagy activating kinases (ULK1/
ULK2), the beclin 1 (BECN1) lipid kinase complex 
and an ubiquitin-like conjugation system [7]. The first 
step of vesicles nucleation depends on the activation of 
phosphatidylinositol 3-kinase catalytic subunit type 3 
(PIK3C3, best known as VPS34), which operates in the 
context of the BECN1 complex [8]. Numerous additional 
proteins interact with BECN1 to activate or inhibit VPS34 
and hence to initiate or suppress autophagy [9-12]. 
The evolutionarily conserved inhibitor of growth 
family (ING) [13] consists of several proteins that are 
generally considered as tumor suppressors and possess 
a similar domain organization [14]. ING proteins are 
highly homologous in the C terminal domain. Each of 
them harbors a plant homeodomain (PHD), a nuclear 
localization signal (NLS), as well as a noncoding region 
(NCR) [13]. The five proteins from the ING family 
(ING1-5) are involved in the regulation of cell cycle 
progression, apoptosis, senescence and DNA repair [15, 
16]. Importantly, all ING proteins modulate the enzymatic 
(de)acetylase activity of histone acetyl transferases (HATs) 
and histone deacetylases (HDACs), thereby influencing 
histone acetylation and gene transcription [17, 18].
In several types of malignancy, the expression of 
ING proteins is reduced [19]. Ovarian, breast, head & 
neck carcinomas, as well as melanomas exhibit decreased 
expression of ING1 [20]. Lung cancer and melanoma often 
show reduced levels of ING2 [21, 22], while gliomas, 
advanced breast cancers and cervical and uroepithelial 
carcinomas underexpress ING4 [23-26]. ING4 loss is also 
an unfavorable prognostic marker in colorectal cancer 
[27] and gastrointestinal stromal tumors [28]. For this 
reason, studies have been launched to (re)express ING4 in 
cancers by means of viral vectors, with some encouraging 
preclinical results [29-33].
ING4 can arrest the cell cycle of HepG2 
hepatocarcinoma cells and induce apoptosis by means 
of activation of the tumor suppressor p53 (TP53) and 
subsequent upregulation of cyclin-dependent kinase 
inhibitor 1 (CDK1, best known as p21) [34]. ING4 
participates to a chromatin-binding multiprotein complex, 
together with TP53 and acetyltransferase E1A Binding 
Protein P300 (EP300), in which TP53 is acetylated 
by EP300, resulting in its transcriptional activation 
[35]. Moreover, ING4 binds to nuclear factor NFκB 
p65 subunit (encoded by the RelA gene), targeting it 
for ubiquitinylation and proteasomal destruction [36], 
meaning that ING4 deficiency can unleash NFκB 
activation and favor angiogenesis in glioblastoma [23]. 
Moreover, the PHD domain of ING4 directly binds to 
histone H3 trimethylated at lysine 4 (H3K4me3), thereby 
recruiting the HBO1 histone HAT complex to target 
promoters, thereby facilitating histone H3 acetylation [37, 
38].
Our group published the results of a yeast-2-
hybrid screen suggesting that ING4 is part of the BECN1 
interactome [12]. Intrigued by this observation, we 
investigated the putative role of ING4 as an autophagy 
regulator. Here we report evidence that ING4 indeed 
interacts with BECN1 in baseline conditions, in human 
cells. Importantly, nutrient depletion, which is (one of) the 
most physiological inducer(s) of autophagy [39], causes 
ING4 to dissociate from BECN1. Moreover, depletion 
of ING4 was sufficient to increase autophagic flux, 
supporting the idea that ING4 acts as a potent endogenous 
inhibitor of autophagy. 
RESULTS AND DISCUSSION
Interaction between ING4 and BECN1. Previous 
work has revealed that the N-terminal domain of ING4 
(4-150 residues among 245) interacts with human 
BECN1 protein in a yeast-two-hybrid system [12]. To 
investigate whether this interaction occurs in human 
cells, we transfected human osteosarcoma U2OS cells 
with Flag-tagged ING4 alone or together with His-tagged 
BECN1. Upon pull-down of Flag-ING4, His-BECN1 was 
detectable in the immunoprecipitate (Figure 1). While 
the immunoprecipitate of Flag-ING4 contained multiple 
acetylated proteins, there was no particular increase in 
protein acetylation of the co-transfected His-BECN1 
(approximate molecular weight 70 kDa), suggesting that 
BECN1 itself is not a target of the acetyltransferase activity 
of the complex in which ING4 takes part (Supplemental 
Figure 1S). Indeed, ING4 is known to interact with the 
acetyltransferase EP300 and the tumor suppressor TP53 
[35]. We therefore investigated whether the interaction 
between Flag-ING4 and His-BECN1 would depend on 
EP300 or TP53. However, the immunoprecipitate of 
Flag-ING4 continued to contain His-BECN1 in human 
colorectal HCT116 cells in which EP300 or TP53 were 
removed by homologous recombination [40] (Figure 2). 
Altogether, these data plead in favor of a direct protein-
protein interaction between ING4 and BECN1, confirming 
the yeast-2-hybrid data [12]. 
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Reduction of the interaction between ING4 and 
BECN1 upon starvation. The most physiological stimulus 
for autophagy induction is starvation [39, 41, 42]. When 
U2OS cells were cultured in nutrient-free (NF) conditions, 
the interaction between Flag-ING4 and His-BECN1 was 
largely reduced (Figure 3A) although starvation barely 
affected the expression levels of Flag-ING4 (Figure 3B). 
These findings suggest that the physiological induction 
of autophagy correlates with alterations in the BECN1 
interactome that include a reduction in the interaction with 
ING4.
Inhibition of autophagy by ING4. Overexpression 
of Flag-ING4 had no major effect on the frequency of 
GFP-LC3-positive puncta in the cytoplasm of HCT116 
and U2OS cells, and failed to cause a major reduction in 
autophagic puncta generated in response to NF conditions 
(Figure 4A, 4B) or autophagy enhancers as Torin1 or 
rapamycin (Rapa) respectively (Supplemental Figure 2S). 
A similar marginal effect could be seen when the ratio 
of lipidated (electrophoretically more mobile) over non-
lipidated (less mobile) LC3 and SQSTM1 (best known 
as p62) degradation were determined by immunoblot as 
a surrogate of the membrane distribution of LC3 (Figure 
4C). This suggests that overexpression of ING4 is unable 
to inhibit autophagy induced by starvation. 
Next, we depleted ING4 using three distinct, 
non-overlapping small interfering RNAs (siRNAs). All 
siRNAs caused an increase in the number of GFP-LC3B-
positive puncta in HCT116 cells, both in fed conditions 
(Figure 5A, 5B) as well as in conditions of starvation, in 
which the depletion of ING4 caused a hyperinduction of 
autophagic puncta (Figure 5A, 5C). In the presence of 
bafilomycin A1 (BAFA1) for 3h, which inhibits the fusion 
of lysosomes with autophagosomes, thus blocking the 
last step of autophagy, the increase in GFP-LC3-positive 
puncta by ING4 depletion was also detectable, both in 
baseline conditions (Figure 5A, 5D) and upon starvation 
(Figure 5A, 5E). The same results were also observed 
Figure 1: Interaction between ING4 and BECN1. Co-immunoprecipitation of BECN1 with ING4. The indicated constructs, 
namely Flag-tagged ING4 (Flag-ING4) and His-tagged BECN1 (His-BECN1) were transfected into U2OS cells alone or in combination. 
The pcDNA3 construct was transfected as internal control of the experiment. Forty-eight hours later, ING4 was immunoprecipitated with 
a specific antibody for Flag and the precipitate was separated by SDS-PAGE and revealed with an antibody specific for His (upper panels) 
or Flag (down panels). Results are representative of three independent experiments. Immunoprecipitation (IP), molecular weight (MW).
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in U2OS cells (Figure 5F-5H). Upon ING4 depletion, 
such cells also manifested a shift in the ratio between 
lipidated and non-lipidated LC3 that is compatible with an 
induction of autophagy, in baseline condition (Figure 5I) 
or in presence of BAFA1 for 3h (Figure 5J). Altogether, 
these data demonstrate that endogenous ING4 can act as 
repressor of autophagy. 
Inhibition of the lipid kinase activity of PIK3C3 
by ING4. Autophagy is tied to the BECN1-dependent 
activation of PIK3C3, resulting in the generation of PI3P 
that can be visualized by means of RFP-tagged short 
peptide (FYVE) that specifically binds to PI3P-containing 
subcellular vesicles [43]. Depletion of ING4 with three 
siRNAs induced the redistribution of RFP-FYVE from a 
diffuse to a punctiform pattern, indicating activation of 
PIK3C3 in baseline or nutrient free conditions (Figure 6A-
6B). Moreover, knockdown of BECN1 or PIK3C3 (Figure 
6C), or its pharmacological inhibition by 3-methyladenine 
(3MA) or wortmannin (WM) abolished the induction 
of GFP-LC3 puncta in response to ING4 depletion 
(siING4A) (Figure 6D-6E). Altogether, these results 
indicate that ING4 inhibition causes autophagy through 
the activation of the lipid kinase activity of the BECN1/
PIK3C3 complex. 
Concluding remarks. The results reported in 
this paper support the contention that ING4 is indeed 
constitutively interacting with BECN1 in mammalian cells 
that are cultured in nutrient-rich conditions. However, 
upon nutrient depletion the BECN1 complex alters its 
composition, in line with the reported plasticity of the 
BECN1 interactome [8], and ING4 dissociates from 
BECN1. Similar dissociation processes have been reported 
Figure 2: EP300 or TP53 are dispensable for the interaction between ING4 and BECN1. Co-immunoprecipitation of 
BECN1 with ING4. The indicated constructs, namely Flag-tagged ING4 (Flag-ING4) and His-tagged BECN1 (His-BECN1) were co 
transfected into HCT116 wild-type (WT), EP300 or TP53 knock-out (KO) cells. The pcDNA3 construct was transfected as internal control 
of the experiment. Forty-eight hours later, ING4 was immunoprecipitated with a specific antibody for Flag and the precipitate was separated 
by SDS-PAGE and revealed with a specific antibody for His and also with a specific antibody for Flag as control. Results are representative 
of three independent experiments. Immunoprecipitation (IP), molecular weight (MW).
Oncotarget89531www.impactjournals.com/oncotarget
for B-cell lymphoma 2 (BCL-2) [9], B-cell lymphoma-
extra large (Bcl-xL) [44], TGFβ-activated kinase 1 
(TAK1)-binding proteins 2 and 3 (TAB2 and TAB3) [12], 
Golgi associated pathogenesis related-1 (GAPR1) [45] 
that all appear to be sufficient to cause BECN1/VPS34 
inhibition because knockdown of BCL-2, Bcl-xL, TAB2, 
TAB3 and GAPR1 is sufficient to stimulate autophagy. 
Moreover, small molecules or peptides designed to 
competitively disrupt the interaction of BECN1 and BCL-
2, Bcl-xL, TAB2, TAB3 and GAPR1 induce the formation 
of GFP-LC3B puncta, [9, 12, 44, 45] further supporting 
the pleiotropic nature of the suppressive interactions 
affecting the BECN1 complex. The mechanisms leading to 
ING4 dissociation from BECN1 in conditions of starvation 
are elusive. Previous work revealed that nutrient depletion 
causes the deacetylation of multiple autophagy-regulatory 
proteins [46] including that of BECN1, which is required 
for autophagy induction [47]. At this stage, it remain to be 
determined whether ING4 can affect BECN1 acetylation 
or whether BECN1 acetylation influences the binding of 
ING4. Irrespective of these unknowns, it appears that the 
dissociation of the ING4-BECN1 interaction correlates 
with the induction of autophagy by other stimuli than 
starvation including addition of torin1, a specific inhibitor 
of mTOR (not shown). 
It appears intriguing that ING4, which is generally 
viewed as a transcription-regulatory factor interacting 
with methylated histones (in particular H3K4me3) [48] 
and DNA [49] has major cytoplasmic functions as well. 
However, ING4 reportedly acts on NF-κB as an E3 
ubiquitin ligase [36], and at least a fraction of ING4 is 
located in the cytoplasm [24], supporting the possibility 
that it exerts important extranuclear functions. Previous 
work has established that TP53 tonically inhibits 
Figure 3: Starvation induces autophagy and reduces the association of BECN1-ING4 in U2OS cells. (A, B) The indicated 
constructs, namely Flag-tagged ING4 (Flag-ING4) and His-tagged BECN1 (His-BECN1) were transfected, alone or in combination, into 
U2OS cells. The pcDNA3 construct was transfected as internal control of the experiment. Forty-eight hours later, cells were treated 
with complete or nutrient free (NF) medium for 6h and consequently, ING4 was immunoprecipitated with a specific antibody for Flag. 
The precipitate was separated by SDS-PAGE and revealed with specific antibodies for His (A) and Flag (B). Immunoprecipitation (IP), 
molecular weight (MW).
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autophagy by an interaction with RB1-inducible coiled-
coil protein 1 (RB1CC1) [50-52] and other mechanisms 
[53]. Another case is provided by the transcription factor 
STAT3 that can inhibit autophagy in the cytoplasm by 
inhibiting eukaryotic translation initiation factor 2-alpha 
kinase 2 (EIF2AK2) [54]. Hence, ING4 apparently 
constitutes yet another example of multifunctional proteins 
that act at several subcellular localizations, namely, as 
nuclear (co)transcription factors and as direct inhibitors of 
the autophagic machinery. 
Altogether, it appears that ING4 constitutes yet 
another regulator of autophagy that acts on the BECN1 
complex, repressing its PIK3C3-mediated lipid kinase 
activity. Future work must determine whether and to which 
extent this function contributes to the tumor suppressive 
action of ING4. 
MATERIALS AND METHODS
Chemicals, cell lines and culture conditions
Unless otherwise indicated, chemicals were 
purchased by Sigma-Aldrich (St Louis, USA), and media 
and supplements for cell culture from Gibco-Invitrogen 
(Carlsbad, USA). Rapamycin was obtained by Tocris 
Bioscience (Ellisville, USA). All cells were maintained 
Figure 4: Overexpression of ING4 has not inhibitory effect on starvation induced autophagy. A. Representative 
photomicrographs of empty vector (pcDNA3) and ING4 (Flag-ING4) overexpressing HCT116 cells stably expressing GFP-LC3 treated in 
presence of complete (CM) or nutrient free (NF) medium for 6h. Hoechst 33342 (Ho, blue) represents nuclear staining. GFP-LC3B puncta 
(green) correspond to autophagosomes. Scale bars: 10 μm. B. Quantification of GFP-LC3B puncta in cells treated in CM or NF medium. 
Data are means ± SD (n = 5). Statistical analysis was performed by Student’s t test in comparison as indicated, # p > 0.05, not significant. 
C. Western blot detection and quantification of LC3 lipidation and SQSTM1 degradation in ING4 overexpressing HCT116 cells upon 
starvation (6h). Actin was used as a loading control. Densitometry was employed to quantify the abundance of lipidated LC3 (LC3-II/LC3I 
ratio) and SQSTM1 (normalized to actin levels). Results are representative of three independent experiments. Molecular weight (MW).
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in standard culture conditions (37°C, 5% CO2). Human 
osteosarcoma U2OS cells (and their GFP-LC3 and FYVE-
RFP-expressing derivatives) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 
10% Fetal bovine serum (FBS) and 10 mM HEPES. 
Human colon carcinoma HCT116 WT and GFP-LC3 
stable expressing cells were maintained in McCoy’s 
medium supplemented with 10% FCS, 100 mg/l sodium 
pyruvate and 10 mM HEPES. For serum and nutrient 
starvation, cells were cultured in serum-free Earle’s 
balanced salt solution (EBSS) for 6 h.
siRNAs, plasmids and transfections
Cells at 50% confluence were transfected 
with a custom-made, non-targeting siRNA (siUNR, 
5′-GCCGGUAUGCCGGUUAAGUdTdT-3′) 
Figure 5: ING4 silencing induces autophagy. A. Representative photomicrographs of ING4 knockdown (siING4A) HCT116 cells 
stably expressing GFP-LC3 treated with complete (CM) or nutrient free (NF) medium for 6h, in presence or absence of 1μM bafilomycin 
A1 (BAFA1) for the last 3h. The non-targeting siRNA (siUNR) was used as internal control of the experiments. Hoechst 33342 (Ho, blue) 
represents nuclear staining. GFP-LC3B puncta (green) correspond to autophagosomes. Scale bars: 10 μm. B.-E. Quantification of GFP-
LC3B dots in ING4 knockdown HCT116 cells treated in CM or NF medium for 6h in presence or absence of BAFA1 for the last 3h. To 
knockdown ING4, 3 different siRNAs were used (siING4A, siING4B and siING4C). Western blot proves the efficiency of siING4s. Data 
are means ± SD (n = 5). Statistical analysis was performed by Student’s t test in comparison with the control condition, ***p < 0.001. F. 
Representative photomicrographs of siING4A knockdown U2OS cells stably expressing GFP-LC3, treated with NF medium for 6h or CM, 
in presence or absence of 1 μM BAFA1 for the last 3h. Hoechst 33342 (Ho, blue) represents nuclear staining. GFP-LC3B puncta (green) 
correspond to autophagosomes. Scale bars: 10 μm. G., H. Quantification of GFP-LC3B dots in siING4A U2OS cells treated in the same 
conditions described in (F). Data are means ± SD (n = 5). Statistical analysis was performed by Student’s t test in comparison with the 
control condition (siUNR, *p < 0.05 ; siING4A, $ p < 0.05). I., J. Western blot detection of ING4 levels, LC3B conversion and SQSTM1 
degradation in U2OS knockdown cells with 3 different ING4 siRNAs in absence (I) or presence (J) of 1 μM BAFA1 for 3h. Actin was used 
as a loading control. Densitometry was employed to quantify the efficiency of the ING4 silencing and abundance of lipidated LC3 (LC3-
II/LC3 I ratio or LC3II/actin ratio when BAFA1 is added) and SQSTM1 (normalized to actin levels). Results are representative of three 
independent experiments. Molecular weight (MW).
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Figure 6: ING4 silencing leads to autophagy due to an increase of the PIK3C3 activity. A. Representative photomicrographs 
of ING4 knockdown (siING4A, siING4B) U2OS cells stably expressing RFP-tagged short peptide (FYVE) treated with complete (CM) or 
nutrient free (NF) medium for 6h. The non-targeting siRNA (siUNR) was used as internal control of the experiments. Hoechst 33342 (Ho, 
blue) represents nuclear staining. RFP-tagged short peptide (red) corresponds to activation of PIK3C3. Scale bars: 10 μm. B. Quantification 
of FYVE puncta upon ING4 silencing (siING4A, siING4B, siING4C), in cells treated with CM or NF for 6h. Data are means ± SD (n = 
5). Statistical analysis was performed by Student’s t test in comparison with the control condition (**p < 0.01, *p < 0.05) or in comparison 
with the NF condition (# p < 0.05). C. Quantification of the number of GFP-LC3B dots in U2OS cells knockdown for ING4 (siING4A), 
Beclin 1 (siBECN1) or PIK3C3 (siPIK3C3) alone or in combination as indicated. Western blot proves the efficiency of ING4, BECN1 and 
PIK3C3 siRNAs. After the silencing cells were treated with complete medium (Untreated), Torin1 (300nM) or Rapamycin (1 μM) for 6h in 
presence of BAFA1 (1 μM) for the last 3h. Data are means ± SD (n = 5). Statistical analysis was performed by Student’s t test in comparison 
with the control condition (***p < 0.001) or in comparison with the Torin1 (### p < 0.001) or Rapamycin ($ p < 0.05, $$$ p < 0.001) 
conditions. D. Representative photomicrographs of ING4 knockdown (siING4A) U2OS cells stably expressing GFP-LC3B treated with 
complete medium (CM) or 3 methyladenine (3MA; 10mM) or wortmannin (WM; 10 μM) for 6h in presence of BAFA1 (1 μM) for the last 
3h. (E) Quantification of the number of GFP-LC3B dots in ING4 knockdown (siING4A) U2OS cells, treated with chemical inhibitors of 
PIK3C3: 3MA or WM for 6h in presence of BAFA1 (1 μM) for the last 3h. Data are means ± SD (n = 5). Statistical analysis was performed 
by Student’s t test in comparison with the CM of siUNR condition (***p < 0.001) or in comparison with the CM of siING4A condition 
(### p < 0.001).
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or with siRNAs specific to PIK3C3 (5′-ACG- 
GTGATGAATCATCTCCdTdT-3′), BECN1 
(5′-UUCCGUAAGGAACAAGUCGG- d TdT-3′), ING4A 
(5′-rgrgrCrCrArCUrgrArgUrAUrAUrgrArgU TT-3′), 
ING4B (5′-rgrCrgrCrArCrArArgUrCrCUrgrArgUrAU TT-
3′) or ING4C (Scbt, Sc-60850). siRNA transfections were 
performed by means of the Lipofectamine® RNAiMAX 
reagent (Invitrogen), according to the manufacturer’s 
instructions. 
Plasmid transfection was carried out by means of 
the FuGENE® HD Transfection Reagent (Promega), as 
recommended by the manufacturer. A plasmid encoding 
a His-BECN1 was co-transfected with the empty vector 
pcDNA3.1 (Invitrogen) or with mammalian expression 
vectors encoding Flag-ING4.
Immunoblotting and immunoprecipitation
Immunoblotting was performed following standard 
procedures. In short, 20μg of protein were separated on 
NuPAGE Novex Bis-Tris 4-12% pre-cast gels (Invitrogen-
Life Technologies, Carlsbad, CA, USA) and transferred to 
Immobilon polyvinylidene difluoride membranes (Merck-
Millipore, Darmstadt, Germany). Unspecific binding was 
reduced by incubating the membranes for 1h in 0.05% 
Tween 20 (v/v in Tris-buffered saline, TBS) supplemented 
with 5% w/v bovine serum albumin (Euromedex, 
Souffelweyersheim, France). Following, membranes 
were probed with antibodies specific for LC3B (CST, 
#2275), SQSTM1 (Abnova, #H00008878-M01), ING4 
(Invitrogen, #40-7700) beta Actin (ab20272), Flag (Sigma, 
#F3040), His (CST, #2365) and Acetylated lysine (CST, 
#9441), BECN1 (Scbt, sc-11427), PIK3C3 (CST, #4263). 
Primary antibodies were revealed with species-specific 
immunoglobulin G conjugated to horseradish peroxidase 
(Southern Biotech, Birmingham, AL, USA), followed 
by chemiluminescence analysis with the SuperSignal 
West Pico reagent by means of an ImageQuant 4000 (GE 
Healthcare, Little Chalfont, UK). A primary antibody that 
specifically recognizes actin was used to ensure equal lane 
loading. Western blot images were quantified by using 
ImageJ software.
For immunoprecipitation, 7×106 cells were lysed 
as previously described [55], and 400 μg of proteins was 
pre-cleared for 1 h with 30 μl of Pure Proteome™ Protein 
G Magnetic Beads (Millipore), followed by incubation 
for 4 h in the presence of 2 μg of specific antibodies or 
IgG controls. Subsequent immunoblotting was carried out 
using TrueBlot™-HRP (eBioscience, San Diego, USA) 
secondary antibodies.
High-throughput assessment of LC3 lipidation 
and FYVE dots
Five x 103 U2OS FYVE-RFP, U2OS or HCT116 
cells stably expressing LC3-GFP were seeded into black 
96-well μclear imaging plates (Greiner Bio-One) and 
allowed to adapt for 24 h. Thereafter the cells were treated 
with nutrient-free medium, 3-methyladenine, wortmannin 
(with or without bafilomycin A1) and respective controls 
and incubated for additional 6h before fixation in 3.7 % 
(w/v) paraformaldehyde (PFA) in phosphate-buffered 
saline (PBS) supplemented with 1 μM Hoechst 33342 
at 4°C over night. Upon fixation, PFA was substituted 
with PBS and a minimum of four view fields per well 
were acquired by means of an ImageXpress micro XL 
automated bioimager (Molecular Devices) equipped with 
a PlanApo 20X/0.75 NA objective (Nikon). 
Data processing and statistical analyses
Unless otherwise specified, independent experiments 
were performed in triplicate parallel instances and 
repeated three times. Microscopy images were segmented 
and analyzed by means of the MetaXpress (Molecular 
Devices) software. Unless otherwise specified, data are 
presented as means ± S.D. Significance was assessed by 
means of two-tailed Student’s t-test. 
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